D. E. Shaw & Co., Inc. Iveric Bio, Inc. Transaction History

D. E. Shaw & Co., Inc.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$26.24 - $39.63 $2.09 Million - $3.15 Million	79,596 Added 38.58%	285,932 $11.2 Million
Q1 2023 May 15, 2023	SELL	$18.67 - $24.56 $11.3 Million - $14.9 Million	-606,631 Reduced 74.62%	206,336 $5.02 Million
Q4 2022 Feb 14, 2023	BUY	$17.24 - $23.95 $12.5 Million - $17.4 Million	726,378 Added 838.88%	812,967 $17.4 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $634,744 - $1.26 Million	67,526 Added 354.23%	86,589 $1.55 Million
Q2 2022 Aug 15, 2022	BUY	$9.12 - $18.9 $173,854 - $360,290	19,063 New	19,063 $183,000

Q1 2022 May 16, 2022	SELL	$12.15 - $16.83 $4.52 Million - $6.26 Million	-371,728 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $5.14 Million - $6.98 Million	371,728 New	371,728 $6.22 Million
Q1 2021 May 17, 2021	SELL	$5.08 - $6.89 $83,083 - $112,685	-16,355 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$5.65 - $7.66 $77,207 - $104,673	-13,665 Reduced 45.52%	16,355 $113,000
Q3 2020 Nov 16, 2020	SELL	$4.01 - $6.29 $1.12 Million - $1.75 Million	-278,782 Reduced 90.28%	30,020 $169,000
Q2 2020 Aug 14, 2020	SELL	$3.06 - $6.6 $612,700 - $1.32 Million	-200,229 Reduced 39.34%	308,802 $1.58 Million
Q1 2020 May 15, 2020	SELL	$2.83 - $8.44 $375,136 - $1.12 Million	-132,557 Reduced 20.66%	509,031 $1.75 Million
Q4 2019 Feb 14, 2020	SELL	$0.93 - $8.58 $37,267 - $343,826	-40,073 Reduced 5.88%	641,588 $5.51 Million
Q2 2019 Aug 14, 2019	BUY	$1.21 - $1.48 $824,809 - $1.01 Million	681,661 New	681,661 $886,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.